|
1
|
Li J, Zhang BN, Fan JH, et al: A
nation-wide multicenter 10-year (1999–2008) retrospective clinical
epidemiological study of female breast cancer in China. BMC Cancer.
11:3642011.
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year
survival: an overview of the randomised trials. Lancet.
365:1687–1717. 2005.PubMed/NCBI
|
|
3
|
Sayer HG, Kath R, Kliche KO and Höffken K:
Premenopausal breast cancer: chemotherapy and endocrine therapy.
Drugs. 62:2025–2038. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Bono JS, Tolcher AW and Rowinsky EK:
The future of cytotoxic therapy: selective cytotoxicity based on
biology is the key. Breast Cancer Res. 5:154–159. 2003.PubMed/NCBI
|
|
5
|
Harris L, Fritsche H, Mennel R, et al:
American Society of Clinical Oncology 2007 update of
recommendations for the use of tumor markers in breast cancer. J
Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park BW, Oh JW, Kim JH, et al:
Preoperative CA 15-3 and CEA serum levels as predictor for breast
cancer outcomes. Ann Oncol. 19:675–681. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee JS, Park S, Park JM, Cho JH, Kim SI
and Park BW: Elevated levels of preoperative CA 15-3 and CEA serum
levels have independently poor prognostic significance in breast
cancer. Ann Oncol. 24:1225–1231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nicolini A, Tartarelli G, Carpi A, et al:
Intensive post-operative follow-up of breast cancer patients with
tumor markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs
CEA-TPA-CA15.3 panel in the early detection of distant metastases.
BMC Cancer. 6:2692006. View Article : Google Scholar
|
|
9
|
Pedersen AC, Sørensen PD, Jacobsen EH,
Madsen JS and Brandslund I: Sensitivity of CA 15-3, CEA and serum
HER2 in the early detection of recurrence of breast cancer. Clin
Chem Lab Med. 51:1511–1519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yonemori K, Katsumata N, Noda A, et al:
Development and verification of a prediction model using serum
tumor markers to predict the response to chemotherapy of patients
with metastatic or recurrent breast cancer. J Cancer Res Clin
Oncol. 134:1199–1206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hashimoto K, Yonemori K, Katsumata N, et
al: Prediction of progressive disease using tumor markers in
metastatic breast cancer patients without target lesions in
first-line chemotherapy. Ann Oncol. 21:2195–2200. 2010. View Article : Google Scholar
|
|
12
|
Molina R, Barak V, van Dalen A, et al:
Tumor markers in breast cancer - European Groupon Tumor Markers
recommendations. Tumor Biol. 26:281–293. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jäger W, Eibner K, Löffler B, Gleixner S
and Krämer S: Serial CEA and CA 15-3 measurements during follow-up
of breast cancer patients. Anticancer Res. 20:5179–5182.
2000.PubMed/NCBI
|
|
14
|
Molina R, Jo J, Filella X, et al: c-erbB-2
oncoprotein, CEA, and CA 15-3 in patients with breast cancer:
prognostic value. Breast Cancer Res Treat. 51:109–119. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lauro S, Trasatti L, Bordin F, et al:
Comparison of CEA, MCA, CA 15-3 and CA 27–29 in follow-up and
monitoring therapeutic response in breast cancer patients.
Anticancer Res. 19:3511–3515. 1999.
|
|
16
|
Tampellini M, Berruti A, Gorzegno G, et
al: Independent factors predict supranormal CA 15-3 serum levels in
advanced breast cancer patients at first disease relapse. Tumor
Biol. 22:367–373. 2001. View Article : Google Scholar
|
|
17
|
Lim E, Vaillant F, Wu D, et al: Aberrant
luminal progenitors as the candidate target population for basal
tumor development in BRCA1 mutation carriers. Nat Med. 15:907–913.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumor. Nature.
490:61–70. 2012. View Article : Google Scholar
|
|
19
|
Lee JS, Park S, Park JM, Cho JH, Kim SI
and Park BW: Elevated levels of serum tumor markers CA 15-3 and CEA
are prognostic factors for diagnosis of metastatic breast cancers.
Breast Cancer Res Treat. 141:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yerushalmi R, Tyldesley S, Kennecke H, et
al: Tumor markers in metastatic breast cancer subtypes: frequency
of elevation and correlation with outcome. Ann Oncol. 23:338–345.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
al-Jarallah MA, Behbehani AE, el-Nass SA,
et al: Serum CA-15.3 and CEA patterns in postsurgical follow-up,
and in monitoring clinical course of metastatic cancer in patients
with breast carcinoma. Eur J Surg Oncol. 19:74–79. 1993.PubMed/NCBI
|
|
22
|
Bidard FC, Hajage D, Bachelot T, et al:
Assessment of circulating tumor cells and serum markers for
progression-free survival prediction in metastatic breast cancer: a
prospective observational study. Breast Cancer Res.
14:R292012.PubMed/NCBI
|
